Ignite Creation Date:
2025-12-24 @ 9:32 PM
Ignite Modification Date:
2026-01-01 @ 7:19 PM
Study NCT ID:
NCT04938232
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-04-03
First Post:
2021-06-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
Sponsor:
Dana-Farber Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-06-04
Start Date Type:
ACTUAL
Primary Completion Date:
2024-04-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-08-01
Completion Date Type:
ESTIMATED
First Submit Date:
2021-06-08
First Submit QC Date:
None
Study First Post Date:
2021-06-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-03-17
Results First Submit QC Date:
None
Results First Post Date:
2025-04-03
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-17
Last Update Post Date:
2025-04-03
Last Update Post Date Type:
ACTUAL